Myogenesis modelled by human pluripotent stem cells uncovers Duchenne muscular dystrophy phenotypes prior to skeletal muscle commitment
Abstract
Duchenne muscular dystrophy (DMD) causes severe disability of children and death of young men, with an incidence of approximately 1/5,000 male births. Symptoms appear in early childhood, with a diagnosis made around 4 years old, a time where the amount of muscle damage is already significant, preventing early therapeutic interventions that could be more efficient at halting disease progression. In the meantime, the precise moment at which disease phenotypes arise – even asymptomatically – is still unknown. Thus, there is a critical need to better define DMD onset as well as its first manifestations, which could help identify early disease biomarkers and novel therapeutic targets. In this study, we have used human induced pluripotent stem cells (hiPSCs) from DMD patients to model skeletal myogenesis, and compared their differentiation dynamics to healthy control cells by a comprehensive multi-omics analysis. Transcriptome and miRnome comparisons combined with protein analyses at 7 time points demonstrate that hiPSC differentiation 1) mimics described DMD phenotypes at the differentiation endpoint; and 2) homogeneously and robustly recapitulates key developmental steps - mesoderm, somite, skeletal muscle - which offers the possibility to explore dystrophin functions and find earlier disease biomarkers. Starting at the somite stage, mitochondrial gene dysregulations escalate during differentiation. We also describe fibrosis as an intrinsic feature of skeletal muscle cells that starts early during myogenesis. In sum, our data strongly argue for an early developmental manifestation of DMD whose onset is triggered before the entry into the skeletal muscle compartment, data leading to a necessary reconsideration of dystrophin functions during muscle development.
Additional Information
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license. bioRxiv preprint first posted online Aug. 4, 2019. We thank the Fondation Maladies Rares (GenOmics grant), Labex Revive (Investissement d'Avenir; ANR-10-LABX-73) and the AFM Téléthon for funding this project. The RNA-Sequencing libraries were processed and sequenced by Integragen (Evry, France). We gratefully acknowledge support from the PSMN (Pôle Scientifique de Modélisation Numérique) of the ENS de Lyon for the computing resources. We thank Dr Nacira Tabti, Dr Elisabeth Le Rumeur, Dr Nathalie Deburgrave and Dr Malgorzata Rak for providing us with specific reagents and antibodies. We thank Dr David Israeli for his feedback on the manuscript and overall discussion on our project.Attached Files
Submitted - 720920.full.pdf
Supplemental Material - media-1.pdf
Supplemental Material - media-2.xlsx
Supplemental Material - media-3.pdf
Supplemental Material - media-4.pdf
Supplemental Material - media-5.pdf
Supplemental Material - media-6.xlsx
Files
Name | Size | Download all |
---|---|---|
md5:4e9c614f15417517762031fa00aa81cf
|
947.7 kB | Preview Download |
md5:7dd117dfe94b7f40051394faa44411e1
|
3.5 MB | Preview Download |
md5:43a6f37f9b88b5febd55d37c919bf1c5
|
54.2 kB | Preview Download |
md5:22bf80d61093ddf95f0cf96213511069
|
402.8 kB | Download |
md5:5cac928ba2feb8e7fc009add047a4001
|
50.5 kB | Preview Download |
md5:19c94bcd5e10f1b6e5cf0ed472653cc6
|
122.8 kB | Download |
md5:ad68d1a5389929937b8fb8cb815b0e5e
|
43.8 kB | Preview Download |
Additional details
- Eprint ID
- 97631
- Resolver ID
- CaltechAUTHORS:20190805-094119649
- Fondation Maladies Rares
- Labex Revive
- ANR-10- LABX-73
- Agence Nationale pour la Recherche (ANR)
- AFM Téléthon
- Created
-
2019-08-05Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field